AML

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

A Study of CRD3874-SI in People With Leukemia

Familial Investigations of Childhood Cancer Predisposition

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

Cardioprotection in AML

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML